Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial

Journal of the Neurological Sciences

Volumn 284, Issue 1-2, 2009, Pages 72-76

  Uchiyama, Shinichiro ^a   Nakaya, Noriaki ^b   Mizuno, Kyoichi ^c   Ohashi, Yasuo ^d   Tajima, Naoko ^e   Kushiro, Toshio ^f   Teramoto, Tamio ^g   Nakamura, Haruo ^h  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Nakaya Clinic   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NIHON UNIVERSITY   (Japan)

^g TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Mitsukoshi Health and Welfare Foundation   (Japan)

Author keywords

MEGA Study; Pravastatin; Proportion of treatment effect (PTE); Randomized controlled trial; Risk factors; Stroke

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; AGING; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GENDER; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SMOKING; STROKE;

ADULT; AGED; ALCOHOL DRINKING; CHOLESTEROL; COMBINED MODALITY THERAPY; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; JAPAN; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OBESITY; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; SMOKING; STROKE;

EID: 67849135072     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.04.002     Document Type: Article

References (32)

1. Mackay J., and Mensah G. The Atlas of Heart Disease and Stroke (2005), World Health Organization, Geneva
2. Neaton J.D., Wentworth D.N., Cutler J., Stamler J., and Kuller L. Risk factors for death from different types of stroke. Multiple risk factor intervention trial research group. Ann Epidemiol 3 (1993) 493-499
3. Berger K., Schulte H., Stögbauer F., and Assmann G. Incidence and risk factor s for stroke in an occupational cohort: the PROCAM Study. Prospective Cardiovascular Muenster Study. Stroke 29 (1998) 1562-1566
4. Bell D.S.H. Stroke in the diabetic patient. Diabetes Care 17 (1994) 213-219
5. Kiyohara Y., Kato I., Iwamoto H., Nakayama K., and Fujishima M. The impact of alcohol and hypertension on stroke incidence in a general Japanese population. The Hisayama Study. Stroke 26 (1995) 368-372
6. Kurth T., Everett B.M., Buring J.E., Kase C.S., Ridker P.M., and Gaziano J.M. Lipid levels and the risk of ischemic stroke in women. Neurology 68 (2007) 5156-5162
7. Wannamethee S.G., Shaper A.G., and Ebrahim S. HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 31 (2000) 1882-1888
8. Shahar E., Chambless L.E., Rosamond W.D., Boland L.L., Ballantyne C.M., McGovern P.G., and Sharrett A.R. Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 34 (2003) 623-631
9. Bots M.L., Elwood P.C., Nikitin Y., Salonen J.T., Freire de Concalves A., Inzitari D., et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 56 (2002) i19-24
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
11. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
12. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
13. Collins R., Armitage J., Parish S., Sleight P., Peto R., and Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
14. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
15. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 68 (2004) 860-867
16. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., et al. Primary prevention of cardiovascular disease in Japan: results of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA), randomised study with pravastatin. Lancet 368 (2006) 1155-1163
17. National Cholesterol Education Program. Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP II) (1993), US Department of Health and Human Services, Washington, DC
18. Guidelines Subcommittee. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17 (1999) 151-183
19. Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., Stewart R.A.H., et al. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 (2002) 1162-1169
20. Rosamond W., et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) 69-171
21. Nakamura Y., Yamamoto T., Okamura T., Kadowaki T., Hayakawa T., Kita Y., et al. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994. Circ J 70 (2006) 960-964
22. Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb 7 (2000) 110-121
23. Kubo M., Kiyohara Y., Kato I., Tanizaki Y., Arima H., Tanaka K., et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama Study. Stroke 34 (2003) 2349-2354
24. Ohira T., Schreiner P.J., Morrisett J.D., Chambless L.E., Rosamond W.D., and Folsom A.R. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 37 (2006) 1407-1412
25. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
26. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
27. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279 (1998) 1615-1622
28. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. PROspective Study of Pravastatin in the Elderly at Risk (PROSPER): a randomized controlled trial. Lancet 360 (2002) 1623-1630
29. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
30. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
31. Amarenco P., Labreuche J., Lavallee P., and Touboul P.-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
32. Jasińska M., Owczarek J., and Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59 (2007) 483-499